Izervay Injection
Product Images NDC 82829-002

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Izervay (NDC 82829-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astellas Pharma Us, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (Izervay 01)

Illustration showing components related to IZERVAY (avacincaptad pegol) 20 mg/mL intravitreal injection. Items include a vial (a), a needle (b), a graduated syringe (c), and separately noted as not included in the kit, an alternative needle (d) and an alcohol wipe (e). The diagram is labeled Figure A.*

FDA Label Image

Figure B (Izervay 02)

An illustration showing a vial of injection with a focus on the small amount of liquid solution at the bottom, highlighted by a line connected to an eye symbol, indicating use for intravitreal administration.*

FDA Label Image

Figure C Figure D (Izervay 03)

Illustrations showing proper handling of an injection vial labeled IZERVAY. Figure C depicts the vial standing upright with a one-minute timer icon above. Figure D shows a hand tapping the vial base with droplets falling from the stopper, emphasizing vial preparation steps for avacincaptad pegol 20 mg/mL intravitreal injection.*

FDA Label Image

Figure E Figure F (Izervay 04)

An instructional illustration showing hands performing vial preparation steps. Figure E depicts peeling off the vial cap, and Figure F shows removal of the vial seal to expose the septum, likely part of medication preparation guidance for IZERVAY injection.*

FDA Label Image

Figure G (Izervay 05)

An instructional illustration showing proper handling technique of an injection syringe and its cap. The right hand holds the syringe cap being twisted and pulled off, while the left hand holds the syringe ready for use. Arrows indicate the direction to twist and remove the cap.*

FDA Label Image

Figure H Figure I (Izervay 06)

Instructional illustration showing two steps of preparing an injection. Figure H depicts a syringe inserting needle vertically into a vial. Figure I shows the vial tilted with a close-up inset highlighting fluid level or needle placement inside the vial. No text or dosage information is visible.*

FDA Label Image

Figure J (Izervay 07)

An instructional illustration showing a hand pulling a syringe upward to withdraw medication from a vial. Close-up highlights measurement markings on the syringe between 0.1 and 0.4 mL. The vial has a label indicating to empty the filter needle completely, demonstrating a step in preparing an intravitreal injection.*

FDA Label Image

Figure K (Izervay 08)

An instructional illustration showing a hand holding a syringe and another hand pulling off the needle cap, demonstrating preparation steps for intravitreal injection of IZERVAY (avacincaptad pegol) 20 mg/mL.*

FDA Label Image

Figure L Figure M (Izervay 09)

Illustrations showing the removal of a cap from a syringe. Figure L depicts a hand twisting and pulling off the syringe cap. Figure M shows the cap being fully removed to expose the syringe needle, with an arrow indicating the direction of removal.*

FDA Label Image

Figure N (Izervay 10)

An instructional diagram showing hands holding a syringe for intravitreal injection. A detail highlights correct and incorrect liquid conditions in the syringe, with a check mark indicating a clear solution at 0.1 and 0.2 mL marks, and an X mark over a syringe containing bubbles or particles.*

FDA Label Image

Figure O (Izervay 11)

An instructional illustration showing a hand holding a syringe with an intravitreal injection needle. A magnified inset highlights the syringe volume measurement at 0.1 mL, focusing on dosage accuracy for the injection.*

FDA Label Image

Futibatinib Str (Izervay 12)

Chemical structure diagram of avacincaptad pegol, the active ingredient in IZERVAY 20 mg/mL intravitreal injection. The image shows the detailed molecule's atomic and bonding arrangement including phosphate groups, nucleotides, and pegol polymer segments.*

FDA Label Image

Figure 2 (Izervay 13)

A line graph depicting the mean change of GA area (mm2) from baseline over time for Izervay 2mg versus Sham. The x-axis represents time from baseline (Baseline, Month 6, Month 12, Month 18), and the y-axis shows the mean change of GA area from 0.00 to 4.00 mm2. The graph compares two groups with Izervay 2mg plotted as a solid line and Sham as a dashed line, showing a gradual increase in GA area for both groups over time.*

FDA Label Image

Figure (Izervay 14)

Box packaging label for IZERVAY 2 mg (0.1 mL of 20 mg/mL solution) avacincaptad pegol intravitreal injection. The label indicates a single-dose vial intended for intravitreal injection, containing one vial, one filter needle, and one syringe. Labeler is Astellas Pharma US, Inc., with NDC 82829-002-01.*

FDA Label Image

Figure (Izervay 15)

Packaging label for IZERVAY 2 mg (0.1 mL of 20 mg/mL solution) intravitreal injection by Astellas Pharma US, Inc. The carton includes one single-dose vial, one filter needle, and one syringe. The label indicates the product is a sample not for sale.*

FDA Label Image

Figure (Izervay 16)

Label of IZERVAY injection containing avacincaptad pegol 20 mg/mL in a single-dose vial for intravitreal use. The label shows a 0.1 mL dose and storage instructions to refrigerate at 2°C to 8°C (36°F to 46°F). Manufactured by IVERIC bio, Inc., with an NDC of 82829-002-01 and marked Rx only.*

FDA Label Image

Figure (Izervay 17)

Packaging label for IZERVAY injection containing avacincaptad pegol at 20 mg/mL concentration, presenting a 0.1 mL single-dose vial delivering 2 mg per dose. The label states intravitreal administration, storage between 2°C to 8°C, manufacturer as IVERIC bio, Inc., and notes it as a sample not for sale.*

FDA Label Image

Figure 3 (Izervay 18)

A line graph showing the mean change of GA area (mm2) from baseline over time at baseline, month 6, and month 12. Two lines compare Izerzay 2 mg (solid line) and Sham (dashed line), with the GA area increasing over time for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.